Question

Should MAGNESIUM vs No Magnesium be used for adults with shock refractory VF/pVT

PROBLEM:	Shock refractory VF/pVT	BACKGROUND:	Mg is not recommended for routine use as an
OPTION:	MAGNESIUM plus standard care		VF/pVT),
COMPARISON:	Placebo plus standard care		
MAIN OUTCOMES:	Survival to discharge with good neuro/ survival to discharge/ROSC		
SETTING:	OHCA/IHCA		
PERSPECTIVE:	Patient perspective		

Assessment

JUDGEMENT	RESEARCH EVIDENCE				ADDITIONAL CONSIDERATIONS				
 Is the problem a priority? ○ No ○ Probably no ○ Probably yes ○ Yes ○ Varies ○ Don't know 	Only those cases where VF/pVT persists after defibrillation attempts require an antiarrhythmic drug. In a large RCT (n= 23,711) of continuous or interrupted chest compressions during cardiopulmonary resuscitation (CPR) for OHCA (Nichol 2015 2203), 22.5% of patients had an initial rhythm of VF/pVT and about 6.7% of all patients received an antiarrhythmic drug (amiodarone 4.7%, lidocaine 2.0%) during CPR. Lidocaine - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Amiodarone - no./total no. (%) 246(12,629 (1.9) 229(1,034 (2.1) 0.46 Alarge observational study (n= 108,079) on airway management using data from the American Heart Association Get With The Guidelines Registry of IHCA reported that about 18% of all patients had an initial rhythm of VF/pVT, and 25% of all patients received an antiarrhythmic drug (amiodarone 17%, lidocaine 8%) during CPR (Andersen 2017 494). This update about the role of antiarrhythmic drugs was prioritized by the ALS Task Force following publication of a large RCT comparing amiodarone, lidocaine and placebo ('ROC ALPS') (Kudenchuk 2016 1711) which was published after the CoSTR in 2015 (Callaway 2015 s84, Soar 2015 e71).						NO NEW EVIDENCE FOR MAGNESIUM IDENTIFIED SINCE 2015 ILCOR COSTR		
How substantial are the desirable anticipated effects <mark>?</mark>	Outcomes [importance]	№ of participants (studies)	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipate Risk with standard care	d absolute effects Risk difference with Intervention + standard care	All studies small, published pre 2001, The four available RCTs had a total of 437 patients, and the most recent was published		
 ○ Trivial ○ Small ○ Moderate ○ Large ○ Varies ○ Don't know 	Magnesium versus plac Survival to hospital discharge with good neurological outcome [Critical] Survival to hospital discharge [Critical] Return of spontaneous circulation [Important]	437 (4 RCTs) (4 RCTs) (4 RCTs)	Very Low Very Low Very Low	RR 2.08 (0.87 to 4.97) RR 1.07 (0.62 to 1.86) RR 0.97 (0.77 to 1.24)	35 per 1,000 90 per 1,000 327 per 1,000	38 more per 1,000 (from 5 fewer to 140 more) 6 more per 1,000 (from 34 fewer to 77 more) 4 more per 1,000 (from 83 lesto 92 more)	the most recent was published in 2002 and followed the 1992 ERC guidelines (Fatovich 1997 237, Thel 1997 1272, Allegra 2001 245, Hassan 2002 57). In addition, in two of these study not all included patients had an arrest rhythm of VF/pVT (Fatovich 1997 237, Thel 1997 1272).		
	JUDGEMENT Is the problem a priority? NO Probably no Probably yes <u>Yes</u> Varies Don't know How substantial are the desirable anticipated effects? Trivial Moderate Large Varies Don't know	JUDGEMENTOnly those cases attempts requir 23,711) of cont during cardiopu 2015 2203), 22 and about 6.7% (amiodarone 4. Udcaine - no,/teal no. (%) A large observar management u Get With The G 18% of all patients re 17%, lidocaine This update ab prioritized by the large RCT com ('ROC ALPS') (after the CoSTI e71).How substantial are the desirable anticipated effects?Outcomes [importance]• Trivial • Moderate • LargeMagnesium versus plat Survival to hospital discharge (critical)• Varies • Don't knowImportance Recent and the cost of th	JUDGEMENTRESIs the problem a priority?Only those cases where attempts require an ant 23,711) of continuous of during cardiopulmonary 2015 2203), 22.5% of p and about 6.7% of all pp (amiodarone 4.7%, lido Uscime - mo/ball no. (%)VariesOnly those cases where attempts require an ant 23,711) of continuous of during cardiopulmonary 2015 2203), 22.5% of p and about 6.7% of all pp (amiodarone 4.7%, lido Uscime - mo/ball no. (%)VariesVaries Don't knowDon't knowThis update about the m prioritized by the ALS T large RCT comparing a ('ROC ALPS') (Kudench after the CoSTR in 2013) e71).How substantial are the desirable anticipated effects?Outcomes [Importance]No of participants fstudies)Orivial Small Ohoderate LargeMagresium versus placebo (grical)322 (grical) (grical)Noderate Don't knowReturn of spontaneous (48Cfs)437 (grical)Varies Don't knowReturn of spontaneous (48Cfs)437 (grical)	JUDGEMENTRESEARCH EIs the problem a priority?Only those cases where VF/pVT attempts require an antiarrhythmi 23,711) of continuous or interrup during cardiopulmonary resuscite 2015 2203), 22.5% of patients has and about 6.7% of all patients red (amiodarone 4.7%, lidocaine 2.0%) VariesVariesYesOn't knowA large observational study (n= 1 management using data from the Get With The Guidelines Registry 18% of all patients received an antiarri 17%, lidocaine 8%) during CPR (This update about the role of anti prioritized by the ALS Task Force large RCT comparing amiodaron ('ROC ALPS') (Kudenchuk 2016 after the CoSTR in 2015 (Callawa e71).How substantial are the desirable anticipated effects?Outcomes (RADE) (Kudenchuk 2016 after the CoSTR in 2015 (Callawa e71).Moderate b LargeMagnesium versus placebo survival to hospital distange with good neurological utcome (RADE)Varies b Don't knowMagnesium versus placebo survival to hospital distange with good neurological utcome (RACI)Varies b Don't knowDon't know	JUDGEMENT RESEARCH EVIDEN Is the problem a priority? Only those cases where VF/pVT persists attempts require an antiarrhythmic drug. 23,711) of continuous or interrupted che during cardiopulmonary resuscitation (C 2015 2203), 22.5% of patients had an in and about 6.7% of all patients received a (amiodarone 4.7%, lidocaine 2.0%) durin 2015 2203, 22.5% of patients had an in and about 6.7% of all patients received a (amiodarone 4.7%, lidocaine 2.0%) durin 2015 2203, 22.5% of patients had an in and about 6.7% of all patients received a (amiodarone 4.7%, lidocaine 2.0%) durin 2015 2203, 22.5% of patients had an in and about 6.7% of all patients received a (amiodarone 4.7%, lidocaine 2.0%) durin 2015 2203, 22.5% of patients had an initial received a (amiodarone - m/tell no. %) 249(1258) (9 2015 2203), 22.5% of patients had an initial set the discrease where vertices and about 6.7% of all patients received an antiarrhythmic fall patients received anticipants f	JUDGEMENTRESEARCH EVIDENCEIs the problem a priority?Only those cases where VF/pVT persists after a attempts require an antiarrhythmic drug. In a la 23,711) of continuous or interrupted chest comp during cardiopulmonary resuscitation (CPR) for 2015 2203), 22.5% of patients had an initial rhy and about 6.7% of all patients received an antia (amiodarone 4.7%, lidocaine 2.0%) during CPF Useries	JUDGEMENT RESEARCH EVIDENCE Is the problem a priority? Only those cases where VF/pVT persists after defibrillation attempts require an antiarrhythmic drug. In a large RCT (n= 23,711) of continuous or interrupted chest compressions during cardiopulmonary resuscitation (CPR) for OHCA (Nichol 2015 2203), 22.5% of patients had an initial rhythm of VF/pVT and about 6.7% of all patients received an antiarrhythmic drug (amiodarone 4.7%, idocaine 2.0%) during CPR. • Varies > Varies • Don't know > Alarge observational study (n= 108,079) on airway management using data from the American Heart Association Get With The Guidelines Registry of IHCA reported that about 18% of all patients received an antiarrhythmic drug (amiodarone 17%, ildocaine 8%) during CPR (Andersen 2017 494). This update about the role of antiarrhythmic drugs was prioritized by the ALS Task Force following publication of a large RCT comparing amiodarone, lidocaine and placebo ('ROC ALPS') (Kudenchuk 2016 1711) which was published after the CoSTR in 2015 (Callaway 2015 s84, Soar 2015 e71). How substantial are the desirable anticipated biother fittigent fittigent method after the CoSTR in 2015 (Callaway 2015 s84, Soar 2015 e71). How substantial are the desirable anticipated biother fittigent fittigent method after the CoSTR in 2015 (Callaway 2015 s84, Soar 2015 e71). How substantial are the desirable anticipated biother fittigent method after the CoSTR in 2015 (Callaway 2015 s84, Soar 2015 e71). How substantial are the desirable anticipated biother fittigent method in the additermeter is additermeter in the additermetere is additor anditer additer and a placebo ('ROC ALPS') (Kudench		

RTAINTY OF EVIDENCE UNDESIRABLE EFFECTS	How substantial are the undesirable anticipated effects? Large Moderate Small Trivial Varies Don't know What is the overall certainty of the evidence of effects? Very low Low Moderate High 	Very low certainty	
VALUES CE	Is there important uncertainty about or variability in how much people value the main outcomes? Important uncertainty or variability Possibly important uncertainty or variability Probably no important uncertainty or variability Mo important uncertainty or variability 		Most people would agree on survival to hospital discharge, Survival with good neurology at hospital discharge. Longer term outcomes, HRQoL not addressed in available studies
BALANCE OF EFFECTS	Does the balance between desirable and undesirable effects favor the intervention or the comparison? • Favors the comparison • Probably favors the comparison • <u>Does not favor either the</u> intervention or the <u>comparison</u> • Probably favors the intervention • Favors the intervention • Varies • Don't know	No	

RESOURCES REQUIRED	How large are the resource requirements (costs)? Large costs Moderate costs Negligible costs and savings Moderate savings Large savings Varies Don't know 	No formal cost-effectiveness studies performed.	Will vary across ILCOR Councils.
CERTAINTY OF EVIDENCE OF	What is the certainty of the evidence of resource requirements (costs)? • Very low • Low • Moderate • High • <u>No included studies</u>	No studies identified.	
COST EFFECTIVENESS	Does the cost-effectiveness of the intervention favor the intervention or the comparison? Favors the comparison Probably favors the comparison Does not favor either the intervention or the comparison Probably favors the intervention Favors the intervention Varies No included studies 	No studies identified.	Not formally studied
EQUITY	What would be the impact on health equity? • Reduced • Probably reduced • Probably no impact • Probably increased • Increased • Varies • Don't know	Uncertain, no relevant studies identified.	

~	Is the intervention acceptable to key stakeholders?	Currently not used/recommended	Not part of routine use, although used in special circumstances in some settings
ACCEPTABILITY	 No Probably no Probably yes Yes Varies Don't know 		
	Is the intervention feasible to implement?	Many services already use IV drugs	Mg available
FEASIBILITY	 No Probably no Probably yes Yes Varies 		
	 Don't know 		

Summary of judgements

		IMPLICATIONS						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know	
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know	
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know	
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies	
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability				
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know	
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know	
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Very low	Low	Moderate	High			No included studies	
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	No included studies	
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know	
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know	
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know	

TYPE OF RECOMMENDATION	Strong recommendation against the option	Conditional recommendation against the option	Conditional recommendation for either the option or the comparison	Conditional recommendation for the option	Strong recommendation for the option		
RECOMMENDATION	We suggest against t	he routine use of mag	nesium in adult natient	s with refractory V/F/n	VT (week		
RECOMMENDATION	recommendation, low-quality evidence).						
JUSTIFICATION	No evidence of benefit, and not currently recommended for routine use						
SUBGROUP CONSIDERATIONS	In making a suggestion against the routine use of magnesium for refractory VF/pVT cardiac arrest, we recognize that there are specific circumstances where magnesium could be considered during refractory VF/pVT (e.g. hypomagnesemia, torsade de pointes). These were not formally reviewed.						
IMPLEMENTATION CONSIDERATIONS	Not currently routinely used						
MONITORING AND EVALUATION	Use of anti-arrhythmic drugs should be included in OHCA and IHCA registry data.						
RESEARCH PRIORITIES	RCH We discussed if magnesium has a beneficial overall effect in cardiac arrest – e.g. neurological outcome, as opposed to antiarrhythmic effect.						